drugset / Trial / NCT01460368

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

NCT01460368

Phase 1 Completed 67 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal. Part B: The purpose of Part B is to evaluate the effect of LY2409021, when given at a dose level much higher than what would normally be given, on the electrical activity of the heart as measured by ECG in relation to placebo and moxifloxacin.

Timeline

Start
2011-10
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ADOMEGLIVANT Small molecule 300 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral